Effects of metformin on glucose uptake by isolated diaphragm from normal and diabetic rats

doi:10.1016/0006-2952(72)90142-6

Biochemical Pharmacology

Volume 21, Issue 23, 1 December 1972, Pages 3153-3162

https://doi.org/10.1016/0006-2952(72)90142-6 Get rights and content

Abstract

The effects of the antidiabetic drug metformin (Nl, Nl-dimethylbiguanide) on glucose uptake by isolated rat diaphragm muscle have been studied. A therapeutic concentration of metformin (10 μg/ml) had no effect on glucose uptake by diaphragm muscle from normal rats incubated in the absence or presence of insulin (100 and 1000 μU/ml), but increased uptake by diaphragm muscle from alloxan-diabetic rats incubated in the presence of insulin (P < 0.05). Diaphragm muscle from normal rats incubated in a medium containing sodium butyrate (0.25 mg/ml) showed a reduction in glucose uptake similar to that seen in muscle from diabetic animals. Metformin (10 μg/ml) also increased glucose uptake by this preparation in the presence of insulin (P < 0.01). A higher concentration of metformin (100 μg/ml) caused a depression of glucose uptake by diaphragms from normal rats, and the necessity for studying therapeutic concentrations of the biguanide drugs is stressed. The relation of these findings to the antidiabetic effect of the drug in man is discussed. The mechanisms involved are discussed in terms of changes in glycogen metabolism.

References (61)

B. Lescure et al.
Biochimie
(1971)
A.N. Wick et al.
J. biol. Chem.
(1958)
A.B. Falcone et al.
J. biol. Chem.
(1962)
W.J.H. Butterfield et al.
Lancet
(1968)
J. Vallance-Owen et al.
Lancet
(1954)
O. Walaas et al.
J. biol. Chem.
(1950)
P.J. Randle et al.
Lancet
(1963)
P.J. Randle et al.
Recent Prog. Horm. Res.
(1966)
D.M. Kipnis et al.
J. biol. Chem.
(1960)
R.K. Crane et al.
J. biol. Chem.
(1953)

W.H. Danforth

J. biol. Chem.

(1965)

F. Huijing et al.

Biochim. biophys. Acta

(1969)

R.A. Altschuld et al.

Ann. N.Y. Acad. Sci.

(1968)

J.J. Connon

European Association for the Study of Diabetes

N.O. Jangaard et al.

Diabetes

(1968)

F. Meyer et al.

Nature, Lond.

(1967)

E. Lorch

Diabetologia

(1971)

W. Creutzfeldt et al.

W. Caspary

Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.

(1971)

J.N. Pereira et al.

Diabetes

(1967)

G.L. Searle et al.

Ann. N.Y. Acad. Sci

(1968)

J.A. Moorhouse et al.

Clin. Res.

(1958)

J.W. Craig et al.

Diabetes

(1960)

R.S. Walker et al.

Br. med. J.

(1960)

S.K. Varma et al.

Br. med. J.

(1972)

R.S. Walker

G. Debry et al.

Diabète

(1964)

A.H.G. Love

Diabetologia

(1969)

H. Daweke et al.

Metabolism

(1963)

R.E. Tranquada et al.

Clin. Res.

(1960)

Cited by (46)

Metformin: Well-known, but unrecognized for the therapeutic doses…
2016, Medecine des Maladies Metaboliques
Plus de 50 ans après la disponibilité de la metformine, nous pouvons légitimement nous poser la question de savoir si une définition de ses taux thérapeutiques est elle aussi disponible. Nous avons ainsi interrogé la littérature scientifique à ce sujet, en croisant les mots « metformine » et « concentrations thérapeutiques ». Quand des taux ont été suggérés en relayant une référence antérieure, nous avons étudié la nature du travail cité et la concordance entre la source et ce qui a été cité à son sujet. Nous avons ainsi identifié 120 documents proposant ou citant en référence 65 valeurs ou fourchettes de valeurs s’échelonnant, respectivement, de 0,129 à 90 mg/L, et de 0 à 1 800 mg/L. Parmi ces publications, quatre seulement étaient des études originales, 54 citaient simplement une référence, les 62 restantes ne citaient même pas de référence. Enfin, les références citées étaient non seulement généralement inappropriées (cas, par exemple, des études réalisées in vitro ou d’études pharmacocinétiques réalisées en aigu), mais non concordantes avec le texte original plus d’une fois sur deux. Force est ainsi de constater que, en raison d’erreurs méthodologiques ou conceptuelles majeures, la communauté diabétologique ne dispose toujours pas de l’information aussi importante que celle relative aux taux thérapeutiques de l’agent antidiabétique de référence.
To establish whether or not there is a literature consensus on the “therapeutic concentrations” of metformin, we systematically searched the scientific literature with the key-words “metformin” and “therapeutic concentration”. When the suggested values were defined by citing a literature reference, the types of studies in cited references and the concordance of data between the citations and theirs sources were studied. We identified 120 documents, which reported or cited 65 different “therapeutic” plasma metformin concentrations or ranges. The values ranged from 0.129 to 90 mg/L, and the lowest and highest boundaries were 0 and 1800 mg/L. Only four original research studies determined a “therapeutic concentration”. Fifty-four publications cited previous studies as defining the therapeutic concentrations, whereas 62 publications did not even cite a supporting reference. The supporting references were mostly reviews, pharmacokinetic studies and in vitro studies. In the 54 publications that cited references, concordance between the wording of the citation and the true nature of the source data was observed in only 23 cases (42.6%). In conclusion, although metformin is the key medication in first-line treatment of type 2 diabetes, major methodological and/or conceptual errors have confounded the literature on its therapeutic concentrations.
Antidiabetic Properties and Mechanism of Action of Orthosiphon stamineus Benth Bioactive Sub-fraction in Streptozotocin-induced Diabetic Rats
2013, JAMS Journal of Acupuncture and Meridian Studies
Citation Excerpt :
In the present study, however, metformin at a concentration of 1 mg/mL in the presence of insulin at 1 IU/mL further increased the glucose utilization. These results are in agreement with the previous study by Frayn and Adnitt [23], which showed that metformin not only enhanced the peripheral utilization of glucose, but also improved the insulin action in muscle and fat tissues. This was attributed, in part, to the increased movement of insulin-sensitive glucose transporters into the cell membrane.
Orthosiphon stamineus is a popular folk medicine widely used to treat many diseases including diabetes. Previous studies have shown that the sub-fraction of chloroform extract was able to inhibit the rise of blood glucose levels in a glucose tolerance test. This study was carried out to evaluate the chronic effect and possible mechanism of action of the bioactive chloroform sub-fraction of O. stamineus using streptozotocin-induced diabetic rats and in vitro methods. Administration of the chloroform extract sub-fraction 2 (Cƒ2-b) at a dose of 1 g/kg twice daily on diabetic rats for 14 days showed a significant lowering (p < 0.05) of the final blood glucose level compared to the pretreatment level. However, there were no significant differences in the plasma insulin levels post-treatment compared to the pretreatment levels for all doses of Cƒ2-b. Conversely, Cƒ2-b at a concentration of 2 mg/mL significantly increased (p < 0.001) the glucose uptake by the rat diaphragm muscle. The increase in glucose uptake was also shown when the muscle was incubated in a solution containing 1 IU/mL of insulin or 1 mg/mL of metformin. Furthermore, the effect of this sub-fraction on glucose absorption in the everted rat jejunum showed that Cƒ2-b at concentrations of 0.5 mg/mL, 1 mg/mL and, 2 mg/mL significantly reduced the glucose absorption of the jejunum (p < 0.05–0.001). Similarly, the absorption of glucose was also inhibited by 1 mg/mL and 2 mg/mL of metformin (p < 0.001). These results suggest that the effect of Cƒ2-b may be due to extra-pancreatic mechanisms. There was no evidence that the plant extract stimulated the release of insulin in order to lower the blood glucose level.
Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes
1994, Biochemical Pharmacology
The effects of glucose and glucagon on the anti-gluconeogenic action of metformin were investigated in normal and diabetic hepatocytes. Glucose production from lactate was elevated by 88% in hepatocytes from fasted normal rats compared with hepatocytes from fed animals. Diabetes caused 3.5- and 2.1-fold increases in hepatic gluconeogenesis under fasting and fed conditions, respectively. Metformin (250 μM) suppressed glucose production by 37% in normal and by 30% in diabetic hepatocytes from fed rats. This drug was more effective (up to 67%) with increasing concentrations of glucose in the medium. Potentiation by metformin of insulin action on gluconeogenesis was elevated significantly (P < 0.01 to 0.001) by glucose in vitro. Metformin (75–250 μM) also counteracted the effects of glucagon at optimal concentrations in normal (32–68%) as well as diabetic (8–46%) hepatocytes. The findings of this study indicate that (i) the anti-gluconeogenic effect of metformin is enhanced by glucose in vivo and in vitro; and (ii) the suppression of glucagon-induced gluconeogenesis by metformin could play a role in its glucose-lowering effects in diabetic conditions.
Biguanides may produce hypoglycemic action in isolated rat hepatocytes through their effects on l-alanine transport
1993, Diabetes Research and Clinical Practice
We investigated the mechanisms of the effects of the biguanides metformin and buformin on hepatic gluconeogenesis in hepatocytes isolated from normal rats. Both 10 nM glucagon and 50 μM dibutyryl cAMP increased [³H]alanine uptake in isolated hepatocytes of normal rats by about 150% and 55%, respectively, compared with the effect of 5 mM alanine alone. Metformin (3 mM) reduced glucagon-stimulated [³H]alanine uptake to the level seen with alanine alone; buformin (3 mM) inhibited glucagon-stimulated [³H]alanine uptake by about 69%. The effects of biguanides on dibutyryl cAMP-stimulated [³H]alanine uptake were similar, but of smaller magnitude compared with those observed in the presence of glucagon. Ouabain (3 mM) had a stonger inhibitory effect on [³H]alanine uptake than the biguanides. However, 3 mM tolbutamide failed to suppress [³H]alanine uptake in the presence or absence of glucagon or dibutyryl cAMP. Our results suggest that the inhibition of alanine uptake, related to a reduction in the $Na^{+} L -alanine$ transport system, is a possible mechanism of biguanide-related inhibition of hepatic gluconeogenesis.
Metformin-An update
1993, General Pharmacology
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance. The effects of metformin include increased glucose uptake, oxidation and glycogenesis by muscle, increased glucose metabolism to lactate by the intestine, reduced hepatic gluconeogenesis and possibly a reduced rate of intestinal glucose absorption. Metformin appears to facilitate steps in the postreceptor pathways of insulin action, and may exert effects that are independent of insulin. In muscle, metformin increases translocation into the plasma membrane of certain isoforms of the glucose transporter. The effects of metformin are generally moderate, and do not cause clinical hypoglycaemia or increased weight gain. Metformin has an antihypertriglyceridaemic effect and exerts various potentially useful effects on haemostasis. A risk of lactic acidosis is negligible provided that the contraindications, particularly renal incompetence are respected.
The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients
1993, Metabolism
The effect of metformin therapy on glucose metabolism was examined in eight overweight newly presenting untreated type II diabetic patients (five males, three females). Patients were treated for 12 weeks with either metformin (850 mg × 3) or matching placebo using a double-bling crossover study design; patients were studied at presentation and at the end of each treatment period. Insulin action was assessed by measuring activation of skeletal muscle glycogen synthase (GS) before and during a 4-hour hyperinsulinemic euglycemic clamp (100 mU · kg⁻¹ · h⁻¹). Metformin therapy was associated with a significant decrease in fasting blood glucose (6.8 ± 0.6 v 8.3 ± 0.9 mmol · L⁻¹, P < .01) and glycosylated hemoglobin ([HbA₁] 7.7% ± 0.4% v 8.5% ± 0.5%, P < .01) levels. Fasting hepatic glucose production (HGP) was also significantly decreased following metformin therapy (1.98 ± 0.13 v 2.41 ± 0.20 mg · kg⁻¹ · min⁻¹, P < .02), whereas fasting insulin and C-peptide concentrations remained unaltered. The decrease in basal HGP correlated closely with the decrease in fasting blood glucose concentration (r = .92, P < .001). Insulin-stimulated glucose uptake was assessed using the hyperinsulinemic euglycemic clamp technique and was increased post-metformin (3.8 ± 0.6 v 3.1 ± 0.7 mg · kg⁻¹ · min⁻¹, P < .05). This was primarily the result of increased nonoxidative glucose metabolism (1.1 ± 0.6 v 0.4 ± 0.6 mg · kg⁻¹ · min⁻¹, P < .05); oxidative glucose metabolism did not change. Metformin had no measurable effect on insulin activation of skeletal muscle GS, the rate-limiting enzyme controlling muscle glucose storage. Thus metformin is an effective drug for use in type II diabetes mellitus, and its hypoglycemic action is likely to result from increased insulin sensitivity at the liver and periphery.

View all citing articles on Scopus

View full text

Effects of metformin on glucose uptake by isolated diaphragm from normal and diabetic rats

Abstract

Biochimie

J. biol. Chem.

J. biol. Chem.

Lancet

Lancet

J. biol. Chem.

Lancet

Recent Prog. Horm. Res.

J. biol. Chem.

J. biol. Chem.

J. biol. Chem.

Biochim. biophys. Acta

Ann. N.Y. Acad. Sci.

European Association for the Study of Diabetes

Diabetes

Nature, Lond.

Diabetologia

Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.

Diabetes

Ann. N.Y. Acad. Sci

Clin. Res.

Diabetes

Br. med. J.

Br. med. J.

Diabète

Diabetologia

Metabolism

Clin. Res.